Press Releases

Date Title  
Toggle Summary BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 11, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as
Toggle Summary BioTime Conducts Sale of Shares in OncoCyte Corporation
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 2, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of common stock of OncoCyte Corporation at a price to
Toggle Summary BioTime Announces Appointment of General Counsel
ALAMEDA, Calif. --(BUSINESS WIRE)--May 22, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary.
Toggle Summary BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
ALAMEDA, Calif. --(BUSINESS WIRE)--May 10, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels
Toggle Summary BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif.
Toggle Summary BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
ALAMEDA, Calif. --(BUSINESS WIRE)--May 6, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office
Toggle Summary BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--May 3, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9 th , 2019, following
Toggle Summary BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
Treatment with OpRegen ® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients ALAMEDA, Calif. --(BUSINESS WIRE)--May 2, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular
Toggle Summary BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 26, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III , M.D., Ph.D., Chief Medical Officer of BioTime , will present at the 26 th Annual
Toggle Summary BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 16, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen ® , a retinal
Toggle Summary BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co.
Toggle Summary BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- BioTime, Inc.
Toggle Summary BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
Company Will Advance Three Clinical Stage Product Candidates Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and Immuno-Oncology ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported
Toggle Summary BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 7, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14 th
Toggle Summary BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 4, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette , PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc.
Toggle Summary BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen ® , a retinal pigment epithelium
Toggle Summary BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
ALAMEDA, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two
Toggle Summary BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
ALAMEDA, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation ( OncoCyte ) (OCX) , a developer of novel, non-invasive tests for the
Toggle Summary BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
ALAMEDA, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has entered into a research and option agreement with Orbit Biomedical Limited (“Orbit Biomedical”). 
Toggle Summary BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
ALAMEDA, Calif. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts , M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective
Toggle Summary BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley , Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor
Toggle Summary BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
Data Suggest That Targeted Intracerebral Delivery of Brain-Derived Neurotrophic Factor Utilizing HyStem® Delivery Platform May Mitigate Ischemic Brain Injury and Restore Functional Benefits ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2018-- BioTime, Inc.
Toggle Summary BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley , Chief Executive Officer of BioTime will be presenting at the LD Micro 11 th Annual Main Event
Toggle Summary BioTime Announces Distribution of AgeX Therapeutics Shares
Distribution to Commence Today at 5:00pm ET Trading to Commence on November 29 th , 2018 Under the Symbol “AGE” ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 28, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced
Toggle Summary BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71 Shares of BioTime for Each Share of Asterias Biotherapeutics ALAMEDA, Calif. & FREMONT, Calif.
Toggle Summary BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution
Toggle Summary BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
Call moved to 5:30 a.m. PT / 8:30 a.m. ET on November 8 th , 2018 ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 6, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously
Toggle Summary BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
Sale of AgeX subsidiary will help support development of BioTime’s core programs Balance owed for remaining portion of transaction totals $21.6 million ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on
Toggle Summary BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 30, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8 th , 2018,
Toggle Summary BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina and Decrease of Drusen Density Observed in Some Patients ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company
Toggle Summary BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
BioTime Shareholders To Receive One Share of AgeX Common Stock for Every 10 Shares of BioTime Common Stock ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board
Toggle Summary BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results
Toggle Summary BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer, will present at the upcoming MicroCap and Ladenburg Thalmann conferences.
Toggle Summary BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois Binette , Senior Vice President and BioTime’s Head of Global Development , will participate in a panel
Toggle Summary BioTime Warrants to Expire on October 1, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 21, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its publicly traded warrants (NYSE American: BTX.WS) that the warrants will expire and not be exercisable after
Toggle Summary BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Former Co-CEO Adi Mohanty to Aid in Transition and Continue to Serve on the Boards of Asterias and OncoCyte Former Co-CEO Michael West to Focus on AgeX CEO Responsibilities ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 18, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company
Toggle Summary BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Regulatory Approvals In-Process; New Record Date to be Set Shortly ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record
Toggle Summary BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia ® and OpRegen ® key data and decisions BioTime and its shareholders participate in potential Juvenescence upside after conversion of note upon Juvenescence IPO BioTime and its
Toggle Summary BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences
Adi Mohanty to participate in panel discussion at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the 20 th
Toggle Summary BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 16, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at the Military Health System Research Symposium (MHSRS) from August 20-23 ,
Toggle Summary BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
BioTime to receive $43 million from Juvenescence BioTime shareholders to receive one share of AgeX common stock for every 10 shares of BioTime common stock held BioTime clinical programs including OpRegen ® for dry-AMD and Renevia ® for volume enhancement are on track Conference call and webcast
Toggle Summary BioTime to Receive $43 Million From Juvenescence
BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics Creates alignment between AgeX Therapeutics and Juvenescence Limited to potentially become leader in the field of aging ALAMEDA, Calif. --(BUSINESS WIRE)--Aug.
Toggle Summary BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 2, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported that Gordon H. Sasaki, M.D., F.A.C.S., has initiated his independent investigator-initiated study of Premvia ™ combined with
Toggle Summary Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
Presentation to include data from new as well as previously treated patients ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract “PI/IIa Study of
Toggle Summary BioTime to Announce Second Quarter 2018 Results on August 2, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of
Toggle Summary BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
- Distribution to BioTime shareholders as of the Record Date on pro rata basis - - Distribution Ratio and Distribution Date to be announced at a later date - ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 10, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on
Toggle Summary BioTime Awarded Grant From the NIH
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743 ,345 from the Small Business Innovation Research (SBIR) program of the National
Toggle Summary BioTime Licenses GMP Cell Line to Goliver Therapeutics
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France -based company focused on addressing liver diseases with
Toggle Summary BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
- Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission - ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 8, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration
Toggle Summary BioTime to Present at the 8th Annual LD Micro Invitational
ALAMEDA, Calif. --(BUSINESS WIRE)--May 30, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer of BioTime , will be presenting at the 8 th Annual LD Micro Invitational
Toggle Summary BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
ALAMEDA, Calif. --(BUSINESS WIRE)--May 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million ) from the Israel Innovation
Toggle Summary BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
Diana V. Do, MD, Professor of Ophthalmology at the Byers Eye Institute , Stanford University School of Medicine David Telander , MD, PhD at The Retinal Consultants Medical Group serving northern California ALAMEDA, Calif. --(BUSINESS WIRE)--May 24, 2018-- BioTime, Inc.
Toggle Summary BioTime Reports First Quarter Results and Recent Corporate Accomplishments
Renevia ® CE Mark application successfully submitted for European approval OpRegen ® cohort 4 initiated in better-vision patients OpRegen ® data slides, conference call and webcast today at 1:30pm PT / 4:30pm ET ALAMEDA, Calif. --(BUSINESS WIRE)--May 10, 2018-- BioTime , Inc. (NYSE American: BTX),
Toggle Summary BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Signs of structural improvement in the retina Signs of a reduction and change in drusen material Signs of engraftment and cell survival have been maintained for over 2 years in some patients ALAMEDA, Calif. --(BUSINESS WIRE)--May 1, 2018-- BioTime, Inc.
Toggle Summary BioTime to Announce First Quarter 2018 Results on May 10, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the
Toggle Summary Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
OpRegen ® is in a Phase I/IIa clinical trial for dry-AMD Retinal Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced
Toggle Summary Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 9, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen ® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy
Toggle Summary BioTime Announces Cash Sale of Ascendance Biotechnology
BioTime subsidiary, AgeX, to receive up to $3.5 million in cash ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 27, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.
Toggle Summary BioTime Reports Fourth Quarter and Fiscal 2017 Results
Renevia ® CE Mark application submitted for European approval OpRegen ® receives DSMB approval to proceed to cohort 4 OpRegen ® cohort 4 will include better vision patients and an array of additional functional assessments ALAMEDA, Calif. --(BUSINESS WIRE)--Mar.
Toggle Summary BioTime Submits CE Mark Application for European Approval of Renevia®
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia ® in Europe .
Toggle Summary BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Continued safety from cohorts 1, 2 and 3 included in assessment by independent DSMB Cohort 4 will focus on earlier stage dry-AMD patients Additional functional data assessments are included in Cohort 4 ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 7, 2018-- BioTime, Inc.
Toggle Summary BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 5, 2018-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2017 financial and
Toggle Summary BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 28, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer of BioTime , will be
Toggle Summary BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
20 years of biopharma clinical development and medical affairs experience Prior Clinical lead for Tysabri at Elan Pharmaceuticals Prior Medical lead for Questcor ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company
Toggle Summary BioTime Appoints Cavan Redmond to Its Board of Directors
Former CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer 30 Years of Executive Management and Corporate Strategy Experience in Biopharma ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology
Toggle Summary Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
OpRegen ® is in a Phase I/IIa clinical trial for dry-AMD Vision Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products
Toggle Summary BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer of BioTime , will participate in
Toggle Summary Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 29, 2018-- BioTime , Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal trial of Renevia ®
Toggle Summary BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer, will be presenting at the
Toggle Summary BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets.
Toggle Summary BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
BioTime expands and strengthens patent estate covering OpRegen ® through 2031 Expanded and strengthened patent coverage of pluripotent cell technology ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and
Toggle Summary BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 20, 2017-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer, and Russell Skibsted , Chief
Toggle Summary Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference
BioTime expects Europe CE Mark submission of Renevia in the first quarter of 2018 Positive data from the pivotal trial of Renevia reinforces potential in multibillion dollar global aesthetics market ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- BioTime , Inc. (NYSE American: BTX), a late-stage,
Toggle Summary Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 30, 2017-- BioTime , Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal trial of Renevia ® in Europe
Toggle Summary BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO
There were no treatment-related serious adverse events after 15 months Signs of engraftment and cell survival have been maintained ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 15, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and
Toggle Summary BioTime to Participate in Upcoming Conferences
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 13, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that its management will participate in the following conferences:
Toggle Summary BioTime Reports Third Quarter Results and Recent Corporate Accomplishments
Over $40M in recent funding Renevia advancing toward anticipated regulatory approval in Europe OpRegen advancing in clinical trials AgeX distribution expected to be completed by early second quarter 2018 ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 9, 2017-- BioTime, Inc.
Toggle Summary BioTime to Participate in the Jefferies 2017 London Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer, and Russell Skibsted
Toggle Summary BioTime to Announce Third Quarter 2017 Results on November 9, 2017
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 24, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release third quarter financial and operating results
Toggle Summary BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment Option
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 17, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced public
Toggle Summary BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 13, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering
Toggle Summary BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 12, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its
Toggle Summary BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
First investigator-led trial of Premvia in U.S. for cosmetic use Clinical trial being conducted by Dr. Aronowitz, a leading Beverly Hills -based Plastic Surgeon ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 11, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused
Toggle Summary BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery
Processa is led by a management team with a proven track record in drug development and drug delivery ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 11, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing
Toggle Summary BioTime to Present at the Cell and Gene Meeting on the Mesa
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 3, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight , SVP, Head of Corporate Development, will present at the
Toggle Summary BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
Filing for Renevia ® CE mark by the end of 2017 Positive long-term data in HIV-associated lipoatrophy reinforces Renevia’s ® potential in multibillion-dollar global facial aesthetics market ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 26, 2017-- BioTime, Inc.
Toggle Summary BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 21, 2017-- BioTime , Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Adi Mohanty will participate in a panel
Toggle Summary BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 20, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer, and Russell Skibsted ,
Toggle Summary BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 20, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer, and Russell Skibsted ,
Toggle Summary BioTime Awarded Grant from the NIH
$1.56 Million Award Accelerates Retinal Restoration Program ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 18, 2017-- BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has
Toggle Summary Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 14, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, and its subsidiaries, today announced the successful conclusion of the challenge to two
Toggle Summary BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 8, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty , Co-Chief Executive Officer, and Russell Skibsted ,
Toggle Summary BioTime to Present at the LD Micro San Francisco Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 5, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight , Senior Vice President, Head of Corporate Development,
Toggle Summary BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 28, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will be presenting one podium presentation and two abstracts at
Toggle Summary BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 14, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately
Toggle Summary BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Conference Call and Live Webcast 4.30pm Eastern Time Today ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 2, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the
Toggle Summary BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data Safety Monitoring Board (DSMB) has authorized the Company to move forward
Toggle Summary BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
Conference Call and Webcast on Wednesday, August 2, 2017 , at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today
Toggle Summary Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 19, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for
Toggle Summary BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
Live Webcast at 12 noon EDT on Tuesday, July 25 ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 18, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader
Toggle Summary Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
As part of the transaction, HBL, which owns 21% of Cellcure's share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime shares to HBL JERUSALEM , June 19, 2017 /PRNewswire/ -- Hadasit Bio-Holdings Ltd.
Toggle Summary BioTime Expands & Advances Ophthalmology Portfolio
Expanded Exclusive, Global License to RPE and Photoreceptor Cells for Use in All Eye Disorders Data Presented at International Society for Stem Cell Research (ISSCR) Conference Translational Vision Sciences & Technology (TVST) Journal Publishes OpRegen® Data ALAMEDA, Calif. --(BUSINESS WIRE)--Jun.
Toggle Summary BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
• Data Reinforce Renevia’s Potential in Multi-Billion Dollar Facial Aesthetics Market • BioTime on Track to File for Renevia CE Mark by End of 2017 • Conference Call Today with Lead Investigator at 4:30 p.m. ET ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 14, 2017-- BioTime, Inc.
Toggle Summary BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
Schedules Conference Call for 4:30pm ET on June 14, 2017 ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 8, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top
Toggle Summary BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
ALAMEDA, Calif. --(BUSINESS WIRE)--May 23, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.
Toggle Summary BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif. --(BUSINESS WIRE)--May 23, 2017-- BioTime , Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime , and its subsidiary Cell Cure Neurosciences Ltd.
Toggle Summary BioTime Presents Retinal Restoration Data at ARVO
Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue Tissue is Highly Similar to Natural Human Tissue ALAMEDA, Calif. --(BUSINESS WIRE)--May 11, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative
Toggle Summary BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif --(BUSINESS WIRE)--May 10, 2017-- BioTime , Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for
Toggle Summary BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
Imaging Analysis Suggests Cell Engraftment and Likely Biological Response ALAMEDA, Calif. --(BUSINESS WIRE)--May 9, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from
Toggle Summary BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
Dr. West to Deliver Presentation on Applying AI to Stem Cell Biology and Participate in Roundtable Discussion ALAMEDA, Calif. --(BUSINESS WIRE)--May 8, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative
Toggle Summary BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Conference Call and Webcast on Wednesday, May 10, 2017 , at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 26, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced
Toggle Summary BioTime to Present Additional Data at Upcoming ARVO
Retinal tissue regeneration presentation added OpRegen ® presentation scheduled for May 8 ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 24, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today
Toggle Summary BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 4, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products
Toggle Summary Key BioTime Patents Upheld by European Patent Office
EPO Rules Patents for OpRegen ® are Valid and Remain in Force as Granted OpRegen ® is in Development to Treat Dry-AMD ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 28, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing
Toggle Summary BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 20, 2017-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer, will be presenting at the Oppenheimer
Toggle Summary BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 16, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results
Toggle Summary Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 15, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase I/IIa clinical trial of OpRegen
Toggle Summary BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 13, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen ® in the advanced
Toggle Summary BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 23, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on
Toggle Summary BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 21, 2017-- BioTime , Inc. (NYSE MKT:BTX) , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.’s financial statements from BioTime’s consolidated
Toggle Summary BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Feb. 15, 2017-- BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public
Toggle Summary CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 15, 2017-- Please replace the release dated February 6, 2017 , with the following corrected version due to multiple
Toggle Summary BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 13, 2017-- BioTime , Inc. (NYSE MKT: BTX) , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted , Chief Financial Officer, will be presenting at the BIO CEO &
Toggle Summary BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Feb. 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 6,481,482 shares
Toggle Summary BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Feb. 9, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an
Toggle Summary BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Draws on a Deep Background at Leading Life Sciences Companies ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 7, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana
Toggle Summary BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 6, 2017-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products
Toggle Summary BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 26, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the NobleCon13 - Noble Capital
Toggle Summary Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
-Data from patients in Cohort 1 and Cohort 2 to be presented- ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 19, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd.
Toggle Summary BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
-Supplying OpRegen ® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration- -Center has Capability to Manufacture Additional BioTime Products- ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Jan. 3, 2017-- BioTime , Inc. (NYSE MKT: BTX and TASE: BTX), a
Toggle Summary BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
Crosses Milestone of 50 Patients Randomized in Pivotal Trial Remains on Track for Top-Line Data by Middle of 2017 ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 14, 2016-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative
Toggle Summary BioTime to Present at Global Bioproduction Summit
Co-CEO Dr. Michael West to Discuss Human Cell Manufacturing for Regenerative Medicine ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 12, 2016-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced
Toggle Summary BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit
Presentation Will Describe the Future of Aging Research and iTR TM , an Emerging Area of Research from BioTime Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to Extend the Healthy Lifespan” ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 8, 2016-- BioTime , Inc. (NYSE MKT: BTX), a
Toggle Summary Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
-3D-imaging Suggests Grafts Retained Volume Over the Assessment Period- -Cells Remained Viable and Proliferated in Renevia Hydrogel- ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 18, 2016-- BioTime , Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company with a focus on pluripotent cell-based
Toggle Summary BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016
-Will Also Present at Young Jewish Professionals Life Sciences & Pharmaceuticals CEO Symposium- ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 10, 2016-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief
Toggle Summary BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Initial data from OpRegen ® trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 3, 2016-- BioTime, Inc.
Toggle Summary Data From BioTime’s Renevia Pivotal Trial in HIV-Associated Facial Liopatrophy to be Presented at the 14th Annual IFATS Meeting on November 17
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 1, 2016-- BioTime , Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia ® in ‘run-in’ patients with HIV-associated facial lipoatrophy from the
Toggle Summary BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development
Brings Wealth of Value Creation Experience to BioTime ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 31, 2016-- BioTime , Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice
Toggle Summary BioTime, Inc. to Announce Third Quarter Results on November 3, 2016
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday, November 3, 2016 , after the
Toggle Summary First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016
- OpRegen at the first dose caused no serious adverse events in the first patient cohort - - Retinal imaging suggests presence and survival of the transplanted cells in the subretinal space for up to one year - ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 20, 2016-- BioTime , Inc. (NYSE MKT and TASE:
Toggle Summary BioTime to Present at the BIO Investor Forum
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 13, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty , Co-Chief Executive Officer, will be presenting at the BIO Investor Forum on Wednesday,
Toggle Summary BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 23, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on
Toggle Summary BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 6, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences: 2016 Gateway Conference at the Four Seasons
Toggle Summary BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine
New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31 new patents between July 3, 2015
Toggle Summary BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
Therapeutic Candidates Continue Clinical Progress Deconsolidation Simplifies Financials Successful Public Equity Offering Strengthens Balance Sheet ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 9, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on
Toggle Summary BioTime, Inc. to Report Second Quarter Results on August 9, 2016
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 27, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday, August 9, 2016 after the
Toggle Summary Landmark Stem Cell Clinical Trial Procedure Performed at Santa Clara Valley Medical Center
– July 13, 2016 /Press Release/ – Santa Clara County, CA.  Last week, physicians at Santa Clara Valley Medical Center (SCVMC), in partnership with Stanford Medicine, successfully completed a surgery injecting stem cells into the spinal cord of a patient who had recently suffered a severe spinal
Toggle Summary BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 5, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced that the underwriters of BioTime , Inc.’s previously announced
Toggle Summary BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering
- Deep Learning Algorithms have the potential to unlock mechanisms of tissue regeneration for applications in age-related disease - ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell
Toggle Summary BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced underwritten public
Toggle Summary BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 16, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176
Toggle Summary BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an
Toggle Summary BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD
- Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to Immediately Proceed to Cohort 2 - ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Jun. 13, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine
Toggle Summary BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will support ongoing development of OpRegen ®, to address a leading cause of blindness, dry-AMD - This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure ALAMEDA,
Toggle Summary BioTime to Present at the Jefferies 2016 Global Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 9, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare Conference to be held in New York
Toggle Summary BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif. --(BUSINESS WIRE)--May 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D. West , Ph.D., will present at the 2016 Oppenheimer 17 th Annual Israel Conference to be held at the David Intercontinental Hotel in Tel-Aviv on Sunday, May
Toggle Summary BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
- First Cohort in OpRegen ® Trial Completed - Management to Host Investor Conference Call on May 17, 2016 at 4:30 p.m. ET ALAMEDA, Calif. --(BUSINESS WIRE)--May 10, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell
Toggle Summary BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference
Presentation topics include: • BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease; and • New Insights into the Fundamental Biology of Human Aging ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 26, 2016-- BioTime, Inc.
Toggle Summary BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31 , to update investors on the Company’s recent accomplishments and objectives for the remainder of 2016.
Toggle Summary BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
-- Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia -- ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its
Toggle Summary BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
FREMONT, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 16, 2016-- Asterias Biotherapeutics, Inc. (NYSE MKT:AST) and BioTime, Inc. (NYSE MKT and TASE:BTX), both clinical-stage regenerative medicine companies with a focus on pluripotent stem cell technology, and BioTime’s wholly owned subsidiary
Toggle Summary BioTime, Inc. to Present at Three Investor Conferences in February
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 1, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, announced today that it will present at the following three investor conferences in February: 18th Annual BIO CEO &
Toggle Summary Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 12, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.1(c) of the Warrant Agreement dated as of October 1, 2013, as amended September 19, 2014 , between BioTime and American Stock Transfer & Trust Company LLC as Warrant
Toggle Summary BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock
Regular Way Trading of OncoCyte common stock on NYSE MKT to begin January 4, 2016 ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 31, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, has completed its previously announced
Toggle Summary BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 30, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the common stock of its subsidiary OncoCyte Corporation (“OncoCyte”) will begin trading today on a
Toggle Summary BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its co-Chief Executive Officer Michael D. West , PhD will deliver a keynote presentation at the 2015
Toggle Summary BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its Board of Directors has set the record date, the distribution ratio, and expected
Toggle Summary BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty , Co-Chief Executive Officer, is scheduled to present at the Oppenheimer 26th
Toggle Summary BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 18, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company’s Board of Directors has appointed Russell Skibsted to the position of Chief
Toggle Summary BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 9, 2015-- BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent accomplishments. “During the third quarter, BioTime and its family of companies achieved
Toggle Summary BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market
Combination of BioTime’s ESI BIO Division and Hepregen to Focus on Next-Generation Metabolism and Safety Screening of New Drugs and Chemicals Provides Access to Hepregen’s Current Customer Base of Major Pharmaceutical and Chemical Companies BioTime Retains Cell Therapy Opportunities While Gaining
Toggle Summary Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 19, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve with Michael D.
Toggle Summary BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution
BioTime Plans Distribution of Shares of Subsidiary OncoCyte Corporation to BioTime Shareholders Planned Distribution to Allow OncoCyte Greater Access to Capital Markets as a Publicly Traded Company ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 7, 2015-- BioTime, Inc.
Toggle Summary BioTime, Inc. Agrees to Sell $5.1 Million of Equity
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 2, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, no par value, at an offering price of
Toggle Summary BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
- Offering Priced at $3.13 Per Share - Inclusion in Six Major Indexes of the Tel Aviv Stock Exchange ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 1, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today
Toggle Summary BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Sep. 28, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for  OpRegen ®, a cell-based
Toggle Summary BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares
Shares to be sold to TASE Index Funds in Israel ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 25, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in a registered direct offering to select investment funds in Israel that
Toggle Summary BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 14, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.29 per share, for a gross purchase price of approximately $8.58 million , to selected
Toggle Summary BioTime Announces Dual Listing on the Tel Aviv Stock Exchange
- Common shares are currently listed on NYSE MKT and will also be listed on the Tel Aviv Stock Exchange (TASE) beginning September 8, 2015 under ticker symbol BTX - Anticipated inclusion in the TASE: TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed Indexes ALAMEDA, Calif.
Toggle Summary ESI BIO - A Division of BioTime, Inc. Launches New Research Technology Platform, VascuNet™ Pericyte Co-Culture Assay
Provides Researchers with In Vitro Assays with Greater Physiological Relevance and Accuracy ALAMEDA, Calif., September 2, 2015 – ESI BIO ( esibio.com ), the stem cell products division of BioTime, Inc. , announced today the release of its most recent technology platform designed to give researchers
Toggle Summary BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 1, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that its Chief Executive Officer Michael D. West , Ph.D. will deliver a keynote presentation at the Stem Cells & Regenerative Medicine Congress in Washington, D.C. from 9:30 to 10:00 a.m.
Toggle Summary BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 28, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime management will present at the Rodman & Renshaw 17th Annual Investment Conference in New York City from 3:00 to 3:25 p.m. EDT on Thursday, September 10, 2015 .
Toggle Summary BioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update. “BioTime’s management team has sharpened its focus on our high priority programs,” said Dr. Michael D.
Toggle Summary BioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development
New patents add to existing portfolio of over 700 issued and pending patents and patent applications world wide owned or licensed to BioTime or its subsidiaries ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the
Toggle Summary BioTime to Present at the Jefferies 2015 Global Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--May 20, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West , PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015 . Dr.
Toggle Summary BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--May 13, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million ) from Israel’s Office of the
Toggle Summary BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--May 11, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs.
Toggle Summary Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision
Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--May 4, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data
Toggle Summary BioTime’s Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington’s Disease
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 27, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime’s wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore ) will be used by UC Irvine scientist Dr.
Toggle Summary BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 22, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime’s subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA ) through which ESI’s
Toggle Summary Positive Clinical Results of OncoCyte’s PanC-Dx™ Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer
Data Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx™ , OncoCyte’s class of proprietary,
Toggle Summary BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 11, 2015-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014 , and highlighted its fourth quarter and recent corporate accomplishments. “In 2014, BioTime and its subsidiaries built strong momentum
Toggle Summary BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 24, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that the first patient was successfully treated in the Company’s pivotal clinical trial in Europe assessing the efficacy of Renevia™ for the treatment of HIV-associated lipoatrophy.
Toggle Summary ESI BIO – A Division of BioTime, Inc., Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of Stem Cell Products
ALAMEDA, Calif., February 23, 2015  – ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth of biotech enterprises, announced an alliance
Toggle Summary Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Feb. 17, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today provided an update on Cell Cure’s product development and partnering activities. On February 16, 2015 , Cell Cure opened the clinical
Toggle Summary ESI BIO - A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific
ALAMEDA, Calif., January 27, 2015  – ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd.
Toggle Summary BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 26, 2015-- BioTime , Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation , ES Cell
Toggle Summary BioTime Appoints Adi Mohanty Chief Operating Officer
Executive Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 29, 2014-- BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet
Toggle Summary BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI
Toggle Summary BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
-OncoCyte’s Proprietary Diagnostic Markers Tested on Patient Samples Collected by Pathologists at Leading US Medical Institution - ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed
Toggle Summary BioTime Appoints Angus C. Russell to Board of Directors
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell , former Chief Executive Officer of Shire plc , has been appointed to BioTime's
Toggle Summary BioTime to Host Investor and Analyst Day on December 15, 2014
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard
Toggle Summary BioTime to Present at the LD Micro VII Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 3, 2014-- BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the LD Micro VII Conference taking
Toggle Summary BioTime Reports Third Quarter Results and Recent Progress
Asterias Biotherapeutics approved for listing on NYSE MKT Asterias’ AST-OPC1 cleared by FDA for Phase 1/2a dose escalation clinical trial for spinal cord injury Cell Cure Neuroscience’s OpRegen ® cleared by FDA for Phase 1/2a dose escalation clinical trial for the dry form of age-related macular
Toggle Summary BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe
Renevia™ to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients globally Patient enrollment initiated; expected to be completed in 2015 ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 4, 2014-- BioTime, Inc.
Toggle Summary BioTime, Inc. Closes $31 Million Financing
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014 , through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the sale of BioTime
Toggle Summary Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 6, 2014-- BioTime , Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at
Toggle Summary BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares
Shares to be sold at the October 2, 2014 closing market share price Funds to be used in part for clinical trials ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered
Toggle Summary BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute
- Final Study Enrollment Exceeds 600 Patients - ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte’s collaborators at The Wistar Institute have completed enrollment of a large, multi-site study
Toggle Summary BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , Ph.D. will present at the Rodman & Renshaw 16th Annual
Toggle Summary BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem®-Based Hydrogel for Vocal Fold Scarring
Investigator-initiated clinical trial may follow preclinical studies ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 28, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault , Ph.D., of the University of Wisconsin and Marc Remacle , M.D.
Toggle Summary BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia ™ has been cleared for marketing as a Class II medical device.
Toggle Summary BioTime Announces Second Quarter 2014 Results and Recent Developments
Three cancer diagnostic products in clinical development IND amendment pending for expanded clinical trials of AST-OPC1 Asterias obtains over $12 million in financing and awarded a $14 million grant FDA provides 510(k) premarket clearance for Premvia ™ ALAMEDA, Calif. --(BUSINESS WIRE)--Aug.
Toggle Summary BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
- New issued patents add to existing estate of over 600 patents and patent applications worldwide in the emerging field of pluripotent stem cell technology - ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 14, 2014-- BioTime , Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime
Toggle Summary BioTime to Present at the Jefferies 2014 Global Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 2, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the Jefferies 2014 Global Healthcare
Toggle Summary BioTime Receives ISO 13485 Certification for Medical Devices
ALAMEDA, Calif. --(BUSINESS WIRE)--May 28, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI ( British Standards Institution ) for design, development, manufacture, and distribution of BioTime HyStem ® hydrogels for cell delivery
Toggle Summary BioTime Announces First Quarter 2014 Results and Recent Developments
Four products currently in clinical development Three therapeutic products currently in late-stage preparation for clinical development Shares of Asterias subsidiary scheduled to trade publicly in near term LifeMap Solutions subsidiary launched to develop mobile health products ALAMEDA, Calif.
Toggle Summary BioTime Raises $6.4 Million in Equity Financing
ALAMEDA, Calif. --(BUSINESS WIRE)--May 5, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014 , the Company received approximately $6.4 million in equity financing.
Toggle Summary BioTime Division ESI BIO Launches New Responsive Design Website to the Scientific Community
ESI BIO’s website has been designed to provide the ultimate user-friendly experience whether on a desktop, tablet or mobile device. Allowing customers access to detailed product information and videos with the option to share information across all major social networking sites.
Toggle Summary BioTime to Present at GTC Stem Cell Summit 2014
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 24, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the GTC Stem Cell Summit 2014 taking
Toggle Summary BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 14, 2014-- BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private companies. Mr.
Toggle Summary BioTime to Present at 13th Annual Needham Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 7, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the 13 th Annual Needham Healthcare
Toggle Summary BioTime To Present at Regen Med Investor Day March 26 in New York
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 25, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the 2 nd Annual Regen Med Investor
Toggle Summary BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 17, 2014-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate
Toggle Summary BioTime Raises $3.5 Million Through Preferred Stock Offering
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 5, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million . The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share,
Toggle Summary BioTime Provides Financing and Product Development Update
$12.6 Million Raised Since October 1, 2013 in At-the-Market Stock Sales Company is Awarded New NIH SBIR Grant Premvia ™ 510(k) Premarket Notification Submitted to FDA for Review ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced the results of its
Toggle Summary BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 18, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the 9 th Annual Stem Cell Summit in
Toggle Summary BioTime Reports Results of Clinical Safety Trial of Renevia™
Renevia ™ Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period Manufacturing and Biocompatibility Information Submitted in a Device Master File to FDA ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 13, 2014-- BioTime, Inc.
Toggle Summary BioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with
Toggle Summary BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime’s CEO, Dr. Michael West will lead a session titled “From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative” today at the
Toggle Summary BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 25, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the 11 th Annual Commercial
Toggle Summary BioTime Announces Third Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter ended September 30, 2013 and highlighted recent corporate
Toggle Summary BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
- Enrollment completed in first safety study of Renevia ™ for dermatological applications - - Two weeks following administration, Renevia ™ appears safe and well tolerated with no serious unexpected adverse events observed to date - ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc.
Toggle Summary BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd. ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business. The research products business will be consolidated into a
Toggle Summary BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City . The presentations will be available on the company website, www.biotimeinc.com .
Toggle Summary BioTime Announces Additional Products in Development Based on HyStem® Technology
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem ® hydrogel technology platform. The first of these new products is ReGlyde TM , a cross-linked thiol-modified hyaluronan
Toggle Summary BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, Inc.
Toggle Summary BioTime Receives Approval to Begin Human Clinical Trials of Renevia
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia™ , a unique biomaterial used as a delivery matrix for autologous
Toggle Summary BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 21, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the expansion of its senior management team with the appointment of Lesley Stolz , Ph.D.
Toggle Summary BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West , PhD will give the keynote address at the MSC 2013 Adult Stem
Toggle Summary BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 9, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and highlighted recent corporate
Toggle Summary BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 16, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West , PhD will present today at the Case Western Reserve University
Toggle Summary BioTime Appoints Henry L. Nordhoff to Board of Directors
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff , former CEO and Chairman of Gen-Probe Inc. , has been appointed to its Board of Directors. “We are pleased to welcome an accomplished healthcare executive of Hank's caliber to
Toggle Summary BioTime, Inc. Closes on $9 Million Financing
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966 . BioTime intends to use the net proceeds from the sale of its common shares and warrants
Toggle Summary BioTime, Inc. to Raise $9 Million in Registered Direct Offering
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 3, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in “units” with each unit consisting of one common share and one-quarter of a
Toggle Summary BioTime Announces Results of Vote at Special Meeting of Shareholders
Shareholders approve proposals related to the planned acquisition of stem cell assets of Geron Corporation by BioTime subsidiary Asterias Biotherapeutics, Inc. ALAMEDA, Calif. --(BUSINESS WIRE)--May. 23, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that at a Special Meeting held on May 21,
Toggle Summary BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the USC Minisymposium:
Toggle Summary BioTime Appoints Franklin Berger to Board of Directors
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 14, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger , CFA, 63, has been appointed to its Board of Directors. “We are pleased to welcome a recognized biotechnology industry expert of Franklin's caliber to BioTime's Board,” said
Toggle Summary BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2013 and highlighted recent corporate
Toggle Summary BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today announced the release of the enhanced LifeMap BioReagents ™ portal ( http://bioreagents.lifemapsc.com/ ) featuring an improved user interface, product descriptions, and customer
Toggle Summary BioTime Announces CFO Succession Plan
Robert W. Peabody to become CFO on May 10, 2013 ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 29, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody , will reassume the additional role of Chief Financial Officer on May 10,
Toggle Summary BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles ( UCLA ) for novel technology related to the treatment of stroke.
Toggle Summary BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate
Toggle Summary BioTime to Present at 25th Annual ROTH Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 13, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr. Michael D. West , Chief Executive Officer, will present a corporate overview of BioTime and
Toggle Summary BioTime Appoints Stephen C. Farrell to Board of Directors
ALAMEDA, Calif., Mar 12, 2013 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C. Farrell has been appointed to its Board of Directors. “We are pleased to welcome an experienced executive of Steve’s caliber to BioTime’s board,” said Alfred D.
Toggle Summary BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing
A total of $17.6 million in new capital raised by BioTime and its subsidiaries since October 2012 ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and Warrant Purchase Agreement with Romulus Films, Ltd.
Toggle Summary BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration
LifeMap Sciences’ discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 4, 2013-- BioTime, Inc.
Toggle Summary BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , PhD will present at the Scale-Up and Manufacturing of
Toggle Summary BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European regulatory authorities for
Toggle Summary BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets
Investor Commits to $10 Million Financing ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron
Toggle Summary BioTime Announces the Appointment of Jeffrey Janus as Vice President
Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 20, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr.
Toggle Summary BioTime Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct
Toggle Summary BioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West , Ph.D. will provide an update today on five products being
Toggle Summary BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 29, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , Ph.D. will present at the World Stem Cell Summit 2012 in
Toggle Summary BioTime Announces Passing of Director Abraham E. Cohen
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 26, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham ( Barry) E. Cohen , a member of its Board of Directors, passed away on Thursday, November 22, 2012 at the age of 76. Mr. Cohen has been a valued member of the Board of Directors and
Toggle Summary BioTime and BioTime Acquisition Corporation Announce Combined $10 Million Financing
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private investor to
Toggle Summary BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation .
Toggle Summary BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 14, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ ( http://bioreagents.lifemapsc.com/ ), a new portal offering researchers access to BioTime’s research product lines including
Toggle Summary BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 and highlighted
Toggle Summary BioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Nov. 7, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that they have entered into a share purchase agreement through which BioTime agreed to purchase 87,456 Cell Cure ordinary shares in
Toggle Summary BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX) today issued the following letter to the shareholders of Geron Corporation (Nasdaq: GERN) regarding Geron’s stem cell assets: October 18, 2012 AN OPEN LETTER TO GERON SHAREHOLDERS Dear Geron Shareholders: As you know,
Toggle Summary BioTime Forms BioTime Acquisition Corporation
Subsidiary will seek to acquire assets and businesses in the stem cell and regenerative medicine fields Dr. Thomas Okarma appointed Chief Executive Officer of the new company ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 28, 2012-- BioTime, Inc. (NYSE MKT: BTX), an Alameda -based company engaged in
Toggle Summary BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 19, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D. West , Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2012 in Cambridge, MA on Thursday, September 20, 2012 . Dr.
Toggle Summary BioTime Obtains Expanded License to HyStem® Technology
- BioTime now holds exclusive worldwide license for all human medical applications of the core HyStem ® technology - ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 27, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of
Toggle Summary BioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers
Collagen Type X determined to be a protein specifically associated with tumor vasculature Antibodies to detect the protein planned to be one component of PanC-Dx TM , a blood-based screen for multiple types of solid tumors ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 16, 2012-- BioTime, Inc.
Toggle Summary BioTime Announces Second Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2012 and highlighted recent corporate
Toggle Summary BioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 17, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC , a
Toggle Summary BioTime CEO Dr. Michael West to Present at the 2012 Agora Financial Investment Symposium
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 16, 2012-- BioTime, Inc. (NYSE MKT:BTX) announced today that Chief Executive Officer Michael D. West , Ph.D. will present at the 2012 Agora Financial Investment Symposium on Tuesday, July 24, 2012 , 4:40 p.m. PDT , at the Fairmont Hotel in Vancouver, British
Toggle Summary BioTime CEO Dr. Michael West to Present at the Jefferies 2012 Global Healthcare Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 30, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that its Chief Executive Officer, Michael D. West , Ph.D., will provide a corporate update at the Jefferies 2012 Global Healthcare Conference in New York City on Monday, June 4, 2012 at 3:30 p.m. ET .
Toggle Summary BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08
ALAMEDA, Calif. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 23, 2012-- XenneX, a Division of LifeMap Sciences , Inc. and BioTime, Inc. (NYSE Amex:BTX), announced today the release of GeneCards® , Version 3.08, on May 20, 2012 . The new release is available at www.genecards.org .
Toggle Summary BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 22, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary LifeMap Sciences, Inc. has entered into a license agreement with Yeda Research and Development Company Ltd , the technology transfer arm of the Weizmann Institute of Science , to
Toggle Summary BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--May. 21, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. today announced that they have completed the acquisition of XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The definitive merger agreement was previously
Toggle Summary HyStem(R)-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease
ALAMEDA, Calif., May 14, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) announced today the publication of a scientific paper demonstrating the effectiveness of HyStem (R) -C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
Toggle Summary BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments
Alameda, Calif., May 10, 2012 - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2012 and highlighted recent corporate accomplishments.
Toggle Summary BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide an update on the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City.
Toggle Summary BioTime Provides Update on ReneviaTM Product Development
- Product development on track for CE Marking by 2013 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia TM (formerly known as HyStem(R)-Rx )
Toggle Summary BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells
- First demonstration of a scalable source of highly purified and identified progenitor cells capable of making definitive (non-hypertrophic) cartilage - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported
Toggle Summary BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
Acquisition will integrate GeneCards (R) and associated databases in a centralized resource called "LifeMap" LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, based on
Toggle Summary BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference
ALAMEDA, Calif., Apr 18, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Future Leaders in the Biotech
Toggle Summary BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012
ALAMEDA, Calif., Apr 16, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 8 th GTC Stem Cell Summit 2012 in
Toggle Summary BioTime Board of Directors Forms Science and Technology Committee
- Advancing product development efforts - ALAMEDA, Calif., Apr 12, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime's technology and
Toggle Summary BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 21, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West , Ph.D., will present a corporate overview of BioTime and
Toggle Summary BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 14, 2012--  BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the fourth quarter and year ended December 31, 2011 and highlighted recent
Toggle Summary BioTime to Present at ROTH 24th Annual Growth Stock Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 8, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Financial Officer, Peter S. Garcia , will present a corporate overview of BioTime and its
Toggle Summary BioTime CEO Michael D. West to Present at New York Stem Cell Summit
ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 17, 2012-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West , Ph.D. will present at the 7th Annual New York Stem Cell
Toggle Summary BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 24, 2012-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100 . Wistar Institute researchers have demonstrated pivotal
Toggle Summary BioTime to Produce Stem Cells for Research in Muscle Disorders
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 3, 2012-- BioTime, Inc. (NYSE Amex: BTX) today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics